tiprankstipranks
Trending News
More News >
Alterity Therapeutics Ltd. (AU:ATH)
ASX:ATH
Advertisement

Alterity Therapeutics (ATH) AI Stock Analysis

Compare
30 Followers

Top Page

AU:ATH

Alterity Therapeutics

(Sydney:ATH)

Select Model
Select Model
Select Model
Underperform 39 (OpenAI - 4o)
Rating:39Underperform
Price Target:
AU$0.00
▼(-100.00% Downside)
Alterity Therapeutics faces significant challenges with profitability and cash flow, which are the most impactful factors in the overall score. The technical analysis provides a neutral to slightly bearish outlook, while the valuation is unattractive due to negative earnings and lack of dividends. These factors collectively result in a low overall stock score.

Alterity Therapeutics (ATH) vs. iShares MSCI Australia ETF (EWA)

Alterity Therapeutics Business Overview & Revenue Model

Company DescriptionAlterity Therapeutics (ATH) is a biotechnology company focused on developing therapeutic solutions to treat neurodegenerative diseases, particularly targeting disorders such as Parkinson's disease and multiple system atrophy. The company's research and development efforts are centered around small molecule compounds that are designed to restore neural function and prevent the progression of these debilitating conditions.
How the Company Makes MoneyAlterity Therapeutics generates revenue primarily through research and development partnerships, grants, and collaborations with other pharmaceutical companies and research institutions. These partnerships often involve upfront payments, milestone payments based on the achievement of certain research or regulatory goals, and royalties on eventual product sales if the developed therapies reach the market. The company may also engage in licensing agreements where it out-licenses its proprietary technology to other firms in exchange for licensing fees and potential future royalties.

Alterity Therapeutics Financial Statement Overview

Summary
Alterity Therapeutics shows strong revenue growth but struggles with profitability and cash flow. The company has minimal debt, providing financial stability, but negative margins and cash flow issues highlight operational inefficiencies.
Income Statement
35
Negative
Alterity Therapeutics shows a significant revenue growth rate of 46.03% in the latest year, indicating strong top-line expansion. However, the company is struggling with profitability, as evidenced by negative net profit margins (-2.23%) and EBIT margins (-2.70%). The consistent negative margins highlight ongoing operational challenges and high costs relative to revenue.
Balance Sheet
45
Neutral
The company maintains a very low debt-to-equity ratio of 0.0037, suggesting minimal leverage and financial risk. However, the return on equity is negative (-28.65%), reflecting the company's inability to generate profits from shareholders' equity. The equity ratio is relatively healthy, indicating a strong equity base compared to total assets.
Cash Flow
30
Negative
Alterity Therapeutics faces challenges with cash flow, as indicated by negative operating cash flow and free cash flow. The free cash flow growth rate is negative (-30.47%), and the operating cash flow to net income ratio is unfavorable, suggesting inefficiencies in converting net income into cash.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue5.44M5.44M4.02M3.92M5.12M4.34M
Gross Profit5.31M5.31M3.80M3.63M4.76M3.98M
EBITDA-14.63M-14.63M-22.95M-17.51M-17.39M-19.36M
Net Income-12.15M-12.15M-19.12M-13.81M-12.85M-15.31M
Balance Sheet
Total Assets46.03M46.03M19.22M27.32M41.36M33.59M
Cash, Cash Equivalents and Short-Term Investments40.66M40.66M12.64M15.77M34.81M28.12M
Total Debt155.46K155.46K159.04K210.38K117.49K65.65K
Total Liabilities3.62M3.62M5.43M4.50M5.89M3.12M
Stockholders Equity42.40M42.40M13.80M22.81M35.47M30.47M
Cash Flow
Free Cash Flow-10.71M-11.45M-12.61M-20.04M-12.43M-17.34M
Operating Cash Flow-10.71M-11.45M-12.61M-20.04M-12.34M-17.33M
Investing Cash Flow-7.50M-7.50M-5.72K-36.46K-89.15K-10.47K
Financing Cash Flow25.54M39.67M9.22M124.34K16.30M36.69M

Alterity Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
AU$119.35M17.3527.24%1.58%0.65%-9.90%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
45
Neutral
AU$121.46M0.66%
43
Neutral
$119.81M-83.09%55.94%
40
Underperform
$150.31M-81.03%-20.79%73.98%
40
Underperform
AU$113.72M-47.98%700.00%26.88%
39
Underperform
$108.75M-42.68%63.46%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:ATH
Alterity Therapeutics
0.01
0.00
0.00%
AU:IMU
Imugene
0.45
-1.19
-72.73%
AU:PAR
Paradigm Biopharmaceuticals
0.40
0.19
90.48%
AU:EZZ
EZZ Life Science Holdings Ltd.
2.59
-1.79
-40.87%
AU:RCE
Recce Pharmaceuticals Ltd.
0.40
-0.13
-24.53%
AU:ALA
Arovella Therapeutics Limited
0.09
-0.07
-43.75%

Alterity Therapeutics Corporate Events

Alterity Therapeutics Publishes Key Neuroimaging Measure for MSA
Aug 4, 2025

Alterity Therapeutics recently announced the publication of a significant neuroimaging measure from its bioMUSE Natural History Study in the Annals of Clinical and Translational Neurology. This measure, known as the MSA Atrophy Index, serves as an imaging marker for diagnosing and tracking the progression of Multiple System Atrophy. The announcement was marked as market-sensitive, as it coincided with a slight increase in the company’s stock price, reflecting its potential impact on Alterity’s market positioning and stakeholder interests.

Alterity Therapeutics Issues Corporate Presentation with Forward-Looking Statements
Jul 31, 2025

Alterity Therapeutics has released a corporate presentation that includes forward-looking statements. These statements, as per US Securities Laws, involve risks and uncertainties that could cause actual results to differ materially from expectations, highlighting the importance of understanding the associated risk factors.

Alterity Therapeutics Advances MSA Treatment with FDA Fast Track Designation
Jul 30, 2025

Alterity Therapeutics has received U.S. FDA Fast Track Designation for its investigational drug ATH434, aimed at treating Multiple System Atrophy (MSA), a neurodegenerative disease with no approved therapies. This designation, along with positive results from Phase 2 clinical trials, highlights the potential of ATH434 to slow disease progression and improve symptoms, reinforcing the company’s confidence in its MSA program as it prepares for further interactions with the FDA.

Alterity Therapeutics Reports Promising Phase 2 Results for MSA Treatment
Jul 28, 2025

Alterity Therapeutics announced positive topline results from its open-label Phase 2 clinical trial of ATH434 in patients with multiple system atrophy (MSA). The trial demonstrated that ATH434 provides clinical benefits by stabilizing neurological symptoms and slowing brain atrophy, with a favorable safety profile. These findings are consistent with previous studies and support the advancement of ATH434 as a potential treatment for MSA, a disease currently lacking modifying medications. The results are promising for stakeholders, indicating potential progress in addressing this challenging condition.

Alterity Therapeutics Unveils New MRI Endpoint for MSA Diagnosis and Progression
Jul 24, 2025

Alterity Therapeutics has announced the publication of a novel MRI endpoint from its bioMUSE Natural History Study in the Annals of Clinical and Translational Neurology. This publication highlights the development of the MSA Atrophy Index, a new neuroimaging measure that uses deep learning to track disease progression in Multiple System Atrophy (MSA) patients. The MSA-AI offers a standardized metric for assessing brain atrophy, which can aid in early diagnosis and improve clinical trial participant selection. The study’s findings underscore the potential of advanced neuroimaging methods to enhance understanding of MSA progression and support the evaluation of disease-modifying therapies.

Alterity Therapeutics Expands Market Presence with New Securities Quotation
Jul 21, 2025

Alterity Therapeutics Limited has announced the quotation of 95,238 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of July 16, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support its ongoing research and development initiatives, potentially strengthening its position in the biotech sector and providing value to its stakeholders.

Alterity Therapeutics Announces Quotation of New Securities on ASX
Jul 17, 2025

Alterity Therapeutics Limited announced the quotation of 79,999,800 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of July 17, 2025. This move is likely to enhance the company’s financial flexibility and market presence, potentially impacting its strategic operations and offering new opportunities for stakeholders.

Alterity Therapeutics Addresses ASX Price Query Amid Market Anticipation
Jul 14, 2025

Alterity Therapeutics Limited has responded to a price query from the ASX regarding a recent increase in its share price and trading volume. The company stated it is unaware of any undisclosed information that could explain the trading activity. However, it highlighted upcoming data releases from its Phase 2 studies and an investor roadshow as potential factors influencing market anticipation.

Alterity Therapeutics Issues 15 Million Unlisted Options to Employees
Jul 3, 2025

Alterity Therapeutics Limited announced the issuance of 15 million unlisted options set to expire in July 2030, as part of an employee incentive scheme. This move is likely to enhance employee engagement and retention, potentially strengthening the company’s operational capabilities and competitive positioning in the biotechnology sector.

Alterity Therapeutics to Update on ATH434 Progress in Upcoming Fireside Chat
Jun 23, 2025

Alterity Therapeutics announced that its CEO, David Stamler, will provide a corporate update during a Fireside Chat hosted by MST Access, focusing on the progress of the ATH434 development program for Multiple System Atrophy. This announcement follows the positive Phase 2 data released in January, highlighting the company’s ongoing efforts to advance its clinical trials and strengthen its position in the biotechnology industry, potentially impacting stakeholders and the market for neurodegenerative disease treatments.

BNY Mellon Increases Stake in Alterity Therapeutics
May 22, 2025

The Bank of New York Mellon Corporation (BNYMC) has increased its substantial holding in Alterity Therapeutics Limited, now holding a 27.03% voting power compared to the previous 26.01%. This change indicates a growing interest and confidence in Alterity’s operations, potentially impacting the company’s market positioning and stakeholder relations.

Alterity Therapeutics Showcases Promising MSA Treatment Advances
May 12, 2025

Alterity Therapeutics announced significant findings from its clinical programs at the 2025 International MSA Congress, highlighting the efficacy of its ATH434 treatment in reducing disease severity and improving symptoms in MSA patients. The introduction of the MSA Atrophy Index as a diagnostic and monitoring tool, along with insights from the bioMUSE study, underscores Alterity’s commitment to advancing MSA treatment and enhancing diagnostic capabilities, potentially impacting patient care and clinical practices.

BNY Mellon Increases Stake in Alterity Therapeutics
May 11, 2025

The Bank of New York Mellon Corporation (BNYMC) has increased its voting power in Alterity Therapeutics Limited from 24.95% to 26.01%, as of May 8, 2025. This change in substantial holding indicates a strengthened position for BNYMC in the company, potentially impacting Alterity’s strategic decisions and shareholder dynamics.

Alterity Therapeutics to Showcase MSA Research at 2025 Congress
May 7, 2025

Alterity Therapeutics announced its participation in the 2025 International MSA Congress, where it will present multiple oral and poster presentations on its clinical programs for Multiple System Atrophy (MSA). The presentations will highlight the Phase 2 data for ATH434, which has shown significant clinical efficacy and safety in treating MSA. The company’s involvement in the congress underscores its commitment to advancing MSA research and care, further supported by the recent Fast Track Designation for ATH434 by the US FDA.

Alterity Therapeutics’ ATH434 Receives FDA Fast Track Designation for MSA Treatment
May 5, 2025

Alterity Therapeutics announced that the U.S. FDA has granted Fast Track designation for its lead candidate, ATH434, aimed at treating Multiple System Atrophy (MSA). This designation is expected to accelerate the development and review process of ATH434, highlighting its potential to meet the high unmet need for MSA treatments. The Fast Track status allows Alterity to engage more frequently with the FDA, potentially speeding up the path to approval. The company has demonstrated ATH434’s efficacy and safety in Phase 2 trials, showing significant improvements in clinical outcomes for MSA patients.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 07, 2025